Back to results
US 11,965,887 B2Granted
Method of examining possibility of subject having pancreatic cancer
AssigneeTHEORIA Science Inc.
InventorsTakahiro Ochiya, Yusuke Yoshioka
Life of this patent
Estimating the term…
Abstract
A method of examining a possibility of a subject having pancreatic cancer, including measuring GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in a specimen collected from the subject.
Claims6
A method of examining a subject for pancreatic cancer, comprising:
- measuring a concentration of GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in blood collected from the subject having pancreatic cancer before performing treatment on the subject by using an immunoassay method;
- measuring a concentration of GPRC5C present in an exosome in blood collected from the subject after performing the treatment on the subject;
- and
- monitoring a therapeutic effect after performing the treatment on the subject and a decrease in cancer sites of the pancreatic cancer of the subject based on the measuring of the concentration of GPRC5C present in the exosome in blood collected from the subject having pancreatic cancer before performing the treatment and after performing the treatment on the subject,
- wherein the immunoassay method is carried out by using an antibody binding to GPRC5C or a fragment of the antibody and an antibody binding to an antigen specifically expressed in an exosome-specific antigen or a fragment of the antibody, and
- wherein the exosome-specific antigen is CD63, CD9, CD81, CD37, CD53, CD82, CD13, CD11, CD86, ICAM-1 (intercellular adhesion molecule-1), Rab5, Annexin V, or LAMP1 (lysosome-associated membrane protein 1).
3 more elements
A method of monitoring a subject for pancreatic cancer, comprising:
- measuring at least twice consecutively a concentration of GPRC5C (G protein-coupled receptor family C group 5 member C) present in an exosome in blood collected from the subject having pancreatic cancer before performing treatment on the subject by using an immunoassay method;
- and
- measuring a concentration of GPRC5C present in an exosome in blood collected from the subject after performing the treatment on the subject;
- and
- monitoring a therapeutic effect after performing the treatment on the subject and a decrease in cancer sites of the pancreatic cancer of the subject based on the measured concentration of GPRC5C present in the exosome in the blood collected from the subject having pancreatic cancer before performing the treatment and after performing the treatment on the subject,
- wherein the immunoassay method is carried out by using an antibody binding to GPRC5C or a fragment of the antibody and an antibody binding to an antigen specifically expressed in an exosome-specific antigen or a fragment of the antibody, and
- wherein the exosome-specific antigen is CD63, CD9, CD81, CD37, CD53, CD82, CD13, CD11, CD86, ICAM-1 (intercellular adhesion molecule-1), Rab5, Annexin V, or LAMP1 (lysosome-associated membrane protein 1).
4 more elements
Dependencies are inferred from the claim text.